Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
TransThera Sciences (Nanjing), Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, meaning each action is being reviewed independently by different personnel. For the practitioner, this requires a dual-track approach to prosecution, as each examiner will have their own set of requirements.
The busiest examiner, GONZALEZ, LUISALBERTO, is assigned 1 pending office action. Since each of the 2 distinct examiners is responsible for only 1 of the 2 pending office actions, no single individual has a disproportionate impact on the company's current portfolio. However, the presence of 2 distinct art units within the Biotechnology & Pharmaceuticals field suggests that the practitioner may encounter different examination standards or procedural nuances.
Managing 2 pending office actions requires the practitioner to track two separate timelines and sets of examiner feedback. Because the actions are in 2 distinct art units, the practitioner should be prepared for diverse perspectives on the patentability of the claims. The goal is to provide a robust response to GONZALEZ, LUISALBERTO and the other distinct examiner to move both of the 2 pending office actions toward a successful conclusion.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| MAYHEW, BRADLEY SCOTT | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552878 | COMBINED USE OF MULTIKINASE INHIBITOR | MAYHEW, BRADLEY SCOTT | 30d |
| 18711481 | NOVEL APPLICATION OF KINASE INHIBITOR | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711481 | NOVEL APPLICATION OF KINASE INHIBITOR | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711481 | NOVEL APPLICATION OF KINASE INHIBITOR | GONZALEZ, LUISALBERTO | 1624 | §103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18552878 | COMBINED USE OF MULTIKINASE INHIBITOR | MAYHEW, BRADLEY SCOTT | 1621 | §112DP | Final Rejection | 30d | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTransThera Sciences (Nanjing), Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Luisalberto Gonzalez has the most, with 1 of TransThera Sciences (Nanjing), Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
